Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorDELUCCHI, VIRGINIA
dc.contributor.authorFerrari, Alberta
dc.contributor.authorBlondeaux, Eva
dc.contributor.authorMariamidze, Elene
dc.contributor.authorBernstein Molho, Rinat
dc.contributor.authorFrank, Sophie
dc.contributor.authorBalmaña, Judith
dc.date.accessioned2025-11-24T13:52:02Z
dc.date.available2025-11-24T13:52:02Z
dc.date.issued2025-11
dc.identifier.citationBlondeaux E, Delucchi V, Mariamidze E, Bernstein-Molho R, Frank S, Ferrari A, et al. Breastfeeding after breast cancer in young BRCA carriers. JNCI J Natl Cancer Inst. 2025 Nov;117(11):djaf177.
dc.identifier.issn1460-2105
dc.identifier.urihttp://hdl.handle.net/11351/14096
dc.descriptionBreastfeeding; Breast cancer; BRCA carriers
dc.description.abstractBackground We investigated safety of breastfeeding after breast cancer in patients carrying germline BRCA pathogenic or likely pathogenic variants. Methods This was an international, multicenter, hospital-based, retrospective cohort study including BRCA carriers diagnosed with stage I–III invasive breast cancer at age 40 years or younger between January 2000 and December 2020 (NCT03673306). Locoregional recurrences and/or contralateral breast cancers, disease-free survival (DFS), and overall survival (OS) were compared between patients who breastfed after delivery and those who did not. Results Among 4732 patients included from 78 centers worldwide, 659 had a pregnancy after breast cancer diagnosis, of whom 474 delivered a child. After excluding patients with uptake of bilateral risk-reducing mastectomy prior to delivery (n = 225) or unknown breastfeeding status (n = 71), 110 (61.8%) breastfed (median duration 5 months) and 68 (38.2%) did not breastfeed. Compared to patients in the no breastfeeding group, those who breastfed were more frequently nulliparous at breast cancer diagnosis (61.8% vs 45.6%) and did not report prior smoking habit (71.8% vs 57.4%). After a median follow-up of 7.0 years following delivery, 7-year cumulative incidence of locoregional recurrences and/or contralateral breast cancers was 29% in the breastfeeding group and 36% in the no breastfeeding group (adjusted subdistribution hazard ratio [HR] = 1.08, 95% CI = 0.57 to 2.06). No difference in DFS (adjusted hazard ratio [aHR] = 0.83, 95% CI = 0.49 to 1.41) nor in OS (aHR = 1.32, 95% CI = 0.31 to 5.66) was observed. Conclusions Breastfeeding did not appear to be associated with a higher risk of developing locoregional recurrences or contralateral breast cancers, emphasizing the possibility of achieving a balance between maternal and infant needs without compromising oncological safety.
dc.language.isoeng
dc.publisherOxford University Press
dc.relation.ispartofseriesJNCI: Journal of the National Cancer Institute;117(11)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectAnomalies cromosòmiques
dc.subjectMama - Càncer - Aspectes genètics
dc.subjectAlletament
dc.subject.meshBreast Neoplasms
dc.subject.mesh/genetics
dc.subject.meshBreast Feeding
dc.subject.meshGerm-Line Mutation
dc.titleBreastfeeding after breast cancer in young BRCA carriers
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1093/jnci/djaf177
dc.subject.decsneoplasias de la mama
dc.subject.decs/genética
dc.subject.decslactancia materna
dc.subject.decsmutación de la línea germinal
dc.relation.publishversionhttps://doi.org/10.1093/jnci/djaf177
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Blondeaux E, Delucchi V] U.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino, Genova, Italy. [Mariamidze E] Department of Oncology and Haematology, Todua Clinic, Tbilisi, Georgia. [Bernstein-Molho R] Susanne Levy Gertner Oncogenetics Unit, Danek Gertner Institute of Human Genetics, Chaim Sheba Medical Centre affiliated to Tel Aviv University, Tel Hashomer, Israel. [Frank S] Department of Medical Oncology, Institut Curie, Paris, France. [Ferrari A] Hereditary Breast and Ovarian Cancer (HBOC) Unit and General Surgery 3—Senology, Surgical Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. Department of General Surgery, University of Pavia, Pavia, Italy. [Balmana J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Hereditary Cancer Genetics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid40623009
dc.identifier.wos001547623500001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record